Why the study?
Does D-dimer >5000 ng/ml at first venous thromboembolism predict future risk of cancer?
Does D-dimer >5000 ng/ml at first venous thromboembolism predict future risk of cancer?
High D-dimer (>5000 ng/ml) at the time of first VTE may serve as a surrogate marker for underlying malignancy and could guide cancer screening decisions.
Hypothesis-generating for D-dimer-guided cancer screening post-VTE; prospective validation required before clinical adoption.
D-dimer >5000 ng/ml at incident VTE is associated with a higher risk of subsequent cancer within one and two years. High D-dimer levels are also associated with more aggressive tumor biology and poor prognosis in these patients. As D-dimer is routinely measured in the assessment of suspected VTE, it may be a useful surrogate marker for the presence of an underlying malignancy. Our findings may suggest that high plasma D-dimer at incident VTE diagnosis should be taken into consideration when the decision to screen for underlying cancer is made.
No takes yet. Share an insight, caveat, or question.
Gran et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: